We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Western Blotting Processors Market to Reach USD 329 Million by 2028

By LabMedica International staff writers
Posted on 20 Sep 2018
The western blotting processors market is projected to grow at a CAGR of 5.1% from an estimated USD 200 million in 2018 to just under USD 329 million towards the end of 2028, driven partly by the increasing cases of HIV globally as western blot is a confirmed test that can detect anti-HIV antibodies in blood serum samples.

These are the latest findings of Future Market Insights (Valley Cottage, NY, USA), a market intelligence and consulting firm.

The western blotting processors market is highly competitive with the top companies accounting for a major portion of the global sales. More...
Leading companies are acquiring smaller companies and expanding their production capacities to capture a larger share of the global market. Companies in the western blotting processors market are leveraging the available market opportunities to launch their products in full gear in the global market. Product registration followed by commercialization is accelerating the product launch process and creating healthy competition in the global market for western blotting processors. Additionally, manufacturers of western blotting processors are setting up production facilities in other countries to benefit from access to cheap labor and resource expertise, and realign their distribution and customer-oriented strategies.

However, advanced automated western blotting devices, such as high performance western blotting transfer systems, are more highly priced in comparison to their traditional counterparts, thus restricting their adoption in most developing economies. In regions with high labor costs, cheap traditional western blotting processors are still being used to perform protein tests, resulting in time-consuming and high labor cost-inducing processes. Additionally, the global western blotting processors market has witnessed the launch of a few advanced products in recent years. Further, results obtained from the western blotting process are not completely reliable or consistent and the devices are required to be updated regularly for producing more efficient and reliable results. These factors are expected to pose a challenge to the revenue growth of the global western blotting processors market.

Related Links:
Future Market Insights


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Alcohol Testing Device
Dräger Alcotest 7000
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dormant tumor cells evade imaging tests and may later reactivate to spread metastatic breast cancer (Photo courtesy of David A. Litman/Shutterstock)

MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.